154 related articles for article (PubMed ID: 32188385)
1. Non-Alcoholic Fatty Liver Disease and Vascular Disease.
Forlano R; Mullish BH; Nathwani R; Dhar A; Thursz MR; Manousou P
Curr Vasc Pharmacol; 2021; 19(3):269-279. PubMed ID: 32188385
[TBL] [Abstract][Full Text] [Related]
2. Nonalcoholic Fatty Liver Disease (NAFLD) and Cardiovascular Risk: Is Imaging Helpful?
Doumas SA; Tripathi S; Kashikar A; Khuttan A; Kumar A; Singh H; Canakis JP; Ashish K; Dey D; Oppenheim I; Dey AK
Curr Probl Cardiol; 2024 Jan; 49(1 Pt B):102065. PubMed ID: 37652112
[TBL] [Abstract][Full Text] [Related]
3. Non-alcoholic fatty liver disease: what the clinician needs to know.
Machado MV; Cortez-Pinto H
World J Gastroenterol; 2014 Sep; 20(36):12956-80. PubMed ID: 25278691
[TBL] [Abstract][Full Text] [Related]
4. The Global Epidemic of Metabolic Fatty Liver Disease.
Lee ECZ; Anand VV; Razavi AC; Alebna PL; Muthiah MD; Siddiqui MS; Chew NWS; Mehta A
Curr Cardiol Rep; 2024 Apr; 26(4):199-210. PubMed ID: 38376745
[TBL] [Abstract][Full Text] [Related]
5. Performance of the Pooled Cohort Equations in non-alcoholic fatty liver disease: The Multi-Ethnic Study of Atherosclerosis.
Henson JB; Budoff MJ; Muir AJ
Liver Int; 2023 Mar; 43(3):599-607. PubMed ID: 36401810
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers of Hepatic Dysfunction and Cardiovascular Risk.
Lee TB; Kueh MTW; Jain V; Razavi AC; Alebna P; Chew NWS; Mehta A
Curr Cardiol Rep; 2023 Dec; 25(12):1783-1795. PubMed ID: 37971635
[TBL] [Abstract][Full Text] [Related]
7. The Association Between Liver Histology and Cardiovascular Risk: Time to Introduce Steatotic Liver Disease Screening in High-Risk Patient Groups?
Boutari C; Athyros VG
Angiology; 2024 Mar; 75(3):205-207. PubMed ID: 37691291
[No Abstract] [Full Text] [Related]
8. MASLD vs. NAFLD: A better definition for children with obesity at higher risk of kidney damage.
Di Sessa A; Guarino S; Umano GR; Miraglia Del Giudice E; Marzuillo P
J Hepatol; 2024 Feb; 80(2):e87-e89. PubMed ID: 37890724
[No Abstract] [Full Text] [Related]
9. Bioimaging and subclinical cardiovascular disease in low- and middle-income countries.
Vedanthan R; Choi BG; Baber U; Narula J; Fuster V
J Cardiovasc Transl Res; 2014 Nov; 7(8):701-10. PubMed ID: 25245465
[TBL] [Abstract][Full Text] [Related]
10. Steatotic liver disease in rural and regional Victoria, according to the NAFLD and newer diagnostic criteria: retrospective cohort analyses of 2001-03 and 2016-18 data.
Vaz K; Kemp WW; Majeed A; Lubel J; Magliano D; Glenister K; Bourke L; Simmons D; Roberts SK
Med J Aust; 2024 Feb; 220(2):97-99. PubMed ID: 38113294
[No Abstract] [Full Text] [Related]
11. Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD.
Vilarinho S; Ajmera V; Zheng M; Loomba R
Hepatology; 2021 Oct; 74(4):2241-2250. PubMed ID: 34233030
[TBL] [Abstract][Full Text] [Related]
12. Can we use old NAFLD data under the new MASLD definition?
Song SJ; Lai JC; Wong GL; Wong VW; Yip TC
J Hepatol; 2024 Feb; 80(2):e54-e56. PubMed ID: 37541393
[No Abstract] [Full Text] [Related]
13. Defining severe NAFLD based on ICD codes in large cohorts: Balancing feasibility and limitations.
Long L; Zhou X
J Hepatol; 2023 Dec; 79(6):e232-e233. PubMed ID: 37160166
[No Abstract] [Full Text] [Related]
14. Understanding the risks and benefits of policy action in NAFLD.
Rowe IA
J Hepatol; 2023 Jul; 79(1):22-24. PubMed ID: 37023965
[No Abstract] [Full Text] [Related]
15. Prevalence and mortality prognosis of steatotic liver disease phenotypes.
Sun Z; Zhou C; Zhang Y; Li P; Guo J; Lian Z; Ji H
Ann Hepatol; 2024; 29(3):101487. PubMed ID: 38403067
[No Abstract] [Full Text] [Related]
16. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical.
Hagström H; Vessby J; Ekstedt M; Shang Y
J Hepatol; 2024 Feb; 80(2):e76-e77. PubMed ID: 37678723
[No Abstract] [Full Text] [Related]
17. Rising tide of NAFLD in youth: A warning bell and call to action.
Xanthakos S
Hepatology; 2023 Oct; 78(4):1017-1019. PubMed ID: 37278240
[No Abstract] [Full Text] [Related]
18. Reply to: "Defining severe NAFLD based on ICD codes in large cohorts: Balancing feasibility and limitations".
Petermann-Rocha F; Ho FK; Pell JP
J Hepatol; 2023 Dec; 79(6):e233-e234. PubMed ID: 37607622
[No Abstract] [Full Text] [Related]
19. Steatotic liver disease as a new nomenclature for NAFLD from the perspectives of the MENA region: One size fits all this time.
El-Kassas M; Alswat K;
J Hepatol; 2024 Feb; 80(2):e66-e68. PubMed ID: 37619930
[No Abstract] [Full Text] [Related]
20. Prognostic value of non-alcoholic fatty liver disease for predicting cardiovascular events in patients with diabetes mellitus with suspected coronary artery disease: a prospective cohort study.
Ichikawa K; Miyoshi T; Osawa K; Miki T; Toda H; Ejiri K; Yoshida M; Nanba Y; Yoshida M; Nakamura K; Morita H; Ito H
Cardiovasc Diabetol; 2021 Jan; 20(1):8. PubMed ID: 33413363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
